Cardio-oncology

Most active in this area

• FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE

  Barcelona-area biomedical research institute specializing in cancer biology, vascular stem cells, iPSC disease modeling, and 3D tissue engineering.

  “RESILIENCE investigates cardiac protection during anthracycline chemotherapy; PhyCaR explores pseudohypoxia-mediated cardiac regeneration — together representing a new research axis connecting oncology and cardiology.”

  ES24 projects
• SOCIETE EUROPEENNE DE CARDIOLOGIE

  Europe's largest cardiology society, contributing clinical registries, guideline expertise, and pan-European physician networks to cardiovascular research consortia.

  “RESILIENCE (anthracycline cardiotoxicity) and CARDIOCARE (breast cancer cardiotoxicity in elderly) represent a newer research direction from 2021 onward.”

  FR15 projects
• INSTITUT CATALA D'ONCOLOGIA

  Spanish cancer research centre specialising in tobacco control, cancer screening programmes, and genomic diagnostics across European consortia.

  “RESILIENCE (2021) addresses anthracycline-induced cardiotoxicity, signalling a new interest in the intersection of cancer treatment and cardiac safety.”

  ES14 projects
• FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON

  Spanish health research foundation coordinating Europe's largest hematology big data platform, with expertise in blood cancers, regenerative medicine, and precision oncology.

  “Involved in RESILIENCE as third party, studying cardiotoxicity and cardioprotection in lymphoma patients receiving anthracyclines.”

  ES9 projects
• FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL GREGORIO MARANON

  Madrid hospital research foundation specializing in cardiovascular disease, cardio-oncology, Treg cell therapy, and maternal neuroscience across translational clinical studies.

  “RESILIENCE specifically investigates cardioprotection against anthracycline-induced cardiotoxicity in lymphoma patients.”

  ES5 projects